NEW YORK, January 25, 2017 /PRNewswire/ --
Stock-Callers.com brings focus back on the Biotechnology industry to seehow some equities have fared over the last few trading sessions. Under evaluation this morning are: PharmAthene Inc. (NYSE MKT: PIP), Corcept Therapeutics Inc. (NASDAQ: CORT), Navidea Biopharmaceuticals Inc (NYSE MKT: NAVB), and Inotek Pharmaceuticals
On Tuesday, shares in Annapolis, Maryland headquartered PharmAthene Inc. recorded a trading volume of 1.74 million shares, which was above their three months average volume of 976,340 shares. The stock ended the session flat at $3.35. The Company's shares have gained 3.08% in the last one month, 19.64% in the previous three months, and 3.08% on an YTD basis. The stock is trading 5.21% above its 50-day moving average and 24.61% above its 200-day moving average. Moreover, shares of PharmAthene, which develops and commercializes medical counter measures against biological and chemical threats in the US, have a Relative Strength Index (RSI) of 54.89.
On January 19th, 2017, PharmAthene and Altimmune, Inc. announced the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. The combined Company will be a fully-integrated and diversified immunotherapeutics Company with four clinical stage and one preclinical stage programs. PharmAthene will issue shares of common stock to Altimmune's shareholders such that Altimmune's equity holders will own 58.2% of the fully-diluted equity of the combined Company. The combined Company, which will operate as a public Company under the name Altimmune, is expected to trade on the NYSE MKT under the ticker symbol ALT. The proposed transaction does not affect PharmAthene's previously announced special one-time cash dividend of $2.91 per share of common stock. Your complete research report on PIP can be retrieved for free at:
Menlo Park, California headquartered Corcept Therapeutics Inc.'s stock closed the day 0.41% higher at $7.27 with a total trading volume of 558,066 shares. The Company's shares have advanced 4.76% in the previous three months and 0.14% since the start of this year. The stock is trading 13.25% above its 200-day moving average. Additionally, shares of Corcept Therapeutics, which engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the US, have an RSI of 34.54.
On January 23rd, 2017, Corcept Therapeutics announced that it will report preliminary Q4 2016 and 2016 financial results and provide 2017 revenue guidance and a corporate update on January 30th, 2017. The Company will also host a conference call that day at 5:00 p.m. ET. A free report on CORT is just a click away at:
Shares in Dublin, Ohio headquartered Navidea Biopharmaceuticals Inc recorded a trading volume of 510,308 shares, and ended yesterday's trading session 1.71% lower at $0.58. The stock is trading below its 50-day moving average by 18.05%. Shares of the Company, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, have an RSI of 36.51. Sign up for your complimentary research report on NAVB at:
Lexington, Massachusetts headquartered Inotek Pharmaceuticals Corp.'s stock finished Tuesday's session flat at $1.52 with a total trading volume of 602,826 shares. The Company's are trading below their 50-day moving average by 71.12%. Shares of the Company, which focuses on the discovery, development, and commercialization of therapies for glaucoma and other diseases of the eye in the US, have an RSI of 19.38.
On January 03rd, 2017, Inotek Pharmaceuticals announced top-line results of MATrX-1, the first pivotal Phase-3 trial of trabodenoson for the treatment of primary open-angle glaucoma or ocular hypertension. The trial did not achieve its primary endpoint of superiority in reduction of intraocular pressure compared with placebo at all 12 time points. This was, in part, due to a placebo response that was 2-3 mmHg greater than that observed in Phase-2. Trabodenoson, the Company's lead clinical candidate, is a first-in-class, highly selective adenosine mimetic targeting the A1 subreceptor.
On January 04th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $22 a share to $7 a share. Register for free on Stock-Callers.com and download the latest research report on ITEK at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Ovarian cancer refers to cancer of ovaries. It is called the "Silent killer", as it is difficult to ...
Schizoaffective disorder is a serious mental disorder in which the individual reflects symptoms ...
When a person overeats, he is unable to control his hunger pangs, while during an emotional/binge ...View All